Abstract:Mitochondria share extensive evolutionary conservation across nearly all living species. This homology allows robust insights to be gained into pathophysiologic mechanisms and therapeutic targets for the heterogeneous class of primary mitochondrial diseases through the study of diverse in vitro cellular and in vivo animal models. Dramatic advances in genetic technologies, ranging from RNA interference to achieve graded knock‐down of gene expression to CRISPR/Cas‐based gene editing that yields a stable gene knock‐out or targeted mutation knock‐in, have enabled the ready establishment of mitochondrial disease models for a plethora of individual nuclear gene disorders. These models are complemented and extended by the use of pharmacologic inhibitor‐based stressors to characterize variable degrees, onset, duration, and combinations of acute on chronic mitochondrial dysfunction in individual respiratory chain enzyme complexes or distinct biochemical pathways in mitochondria. Herein is described the rationale for, and progress made in, "therapeutic cross‐training", a novel approach meant to improve the validity and rigor of experimental conclusions when testing therapies by studying treatment effects in multiple, evolutionarily‐distinct species, including C. elegans (invertebrate, worm), D. rerio (vertebrate, zebrafish), M. musculus (mammal, mouse), and/or human patient primary fibroblast cell line models of primary mitochondrial disease. The goal of these pre‐clinical studies is to identify lead therapies from candidate molecules or library screens that consistently demonstrate efficacy, with minimal toxicity, in specific subtypes of mitochondrial disease. Conservation of in vitro and in vivo therapeutic effects of lead molecules across species has proven extensive, where molar concentrations found to be toxic or efficacious in one species are often consistent with therapeutic effects at similar doses seen in other mitochondrial disease models. Phenotypic outcome studies in all models are prioritized at the level of survival and function, to reflect the ultimate goal of developing highly potent therapies for human mitochondrial disease. Lead compounds that demonstrate significant benefit on gross phenotypes may be further scrutinized in these same models to decipher their cellular targets, mechanism(s), and detailed biochemical effects. High‐throughput, automated technologic advances will be discussed that enable efficient, parallel screening in a diverse mitochondrial disease disorders and overarching subclasses of compounds, concentrations, libraries, and combinations. Overall, this therapeutic cross‐training approach has proven valuable to identify compounds with optimal potency and safety profiles among major biochemical subtypes or specific genetic etiologies of mitochondrial disease. This approach further supports rational prioritization of lead compounds, target concentrations, and specific disease phenotypes, outcomes, and subgroups to optimally inform the design of clinical trials that test their efficacy in human mitochondrial disease subjects.

A method to identify and validate mitochondrial modulators using mammalian cells and the worm C. elegans

Cell Models and Drug Discovery for Mitochondrial Diseases

Identification of Small-Molecule Ion Channel Modulators in C. Elegans Channelopathy Models.

0256: A Screening Strategy to Identify Modulators of the Mitochondrial ADP/ATP Translocase (ANT) for Cardioprotection

Mitochondrial Targets for Pharmacological Intervention in Human Disease

A Screenable In Vivo Assay for Mitochondrial Modulators Using Transgenic Bioluminescent Caenorhabditis elegans

The pursuit of precision mitochondrial medicine: Harnessing preclinical cellular and animal models to optimize mitochondrial disease therapeutic discovery

High-Throughput Small Molecule Screen Identifies Modulators of Mitochondrial Function in Neurons

High-Throughput Assay for Modulators of Mitochondrial Membrane Potential Identifies a Novel Compound with Beneficial Effects on Db/db Mice

Chemical mitophagy modulators: Drug development strategies and novel regulatory mechanisms

Investigating impacts of the mycothiazole chemotype as a chemical probe for the study of mitochondrial function and aging

Mitophagy modulation rescues single large-scale mitochondrial DNA deletion (SLSMD) disease symptoms in the C. elegans uaDf5 animal model.

The utility of HepG2 cells to identify direct mitochondrial dysfunction in the absence of cell death

Characterization and Discovery of a Selective Small-Molecule Modulator of Mitochondrial Complex I Targeting a Unique Binding Site.

Deep learning-driven neuromorphogenesis screenings identify repurposable drugs for mitochondrial disease

Combinatorial glucose, nicotinic acid and N-acetylcysteine therapy has synergistic effect in preclinical C. elegans and zebrafish models of mitochondrial complex I disease

Novel approach to quantify mitochondrial content and intrinsic bioenergetic efficiency across organs

Harnessing Mitochondrial Function in Human Diseases Using New Marine-Derived Strategies

Development of a Mitochondria-Based Centrifugal Ultrafiltration/liquid Chromatography/mass Spectrometry Method for Screening Mitochondria-Targeted Bioactive Constituents from Complex Matrixes: Herbal Medicines As a Case Study

Measuring interference of drug-like molecules with the respiratory chain: toward the early identification of mitochondrial uncouplers in lead finding